Protects against Doxorubicin-Induced Cardiotoxicity and Nephrotoxicity.

Yuewen Wang, Xu Chao, Fiaz Ud Din Ahmad, Hailong Shi, Hania Mehboob, Waseem Hassan
Author Information
  1. Yuewen Wang: School of Basic Medical Sciences, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China.
  2. Xu Chao: School of Basic Medical Sciences, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China.
  3. Fiaz Ud Din Ahmad: Department of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur 63100, Pakistan.
  4. Hailong Shi: School of Basic Medical Sciences, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China. ORCID
  5. Hania Mehboob: Department of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur 63100, Pakistan.
  6. Waseem Hassan: Department of Pharmacy, COMSATS University Islamabad, Lahore Campus, Lahore 54000, Pakistan. ORCID

Abstract

Doxorubicin (DOX) is an important anticancer drug used widely in the treatment of leukemia and lymphoma. The suitability of DOX is enhanced by its high therapeutic index, but its potential to cause cardiotoxicity and nephrotoxicity remains a prime concern in anticancer therapeutics. This study is designed to determine the effect of extract (PDE) on DOX-induced cardiotoxicity and nephrotoxicity. Experimental rats were divided into four groups, receiving normal saline 4 ml/kg, DOX alone, and crude extract of PDE at doses of 1 g/kg and 1.5 g/kg in the presence of DOX, respectively, for 21 days. Cardiac enzymes and serum and urinary sodium and potassium levels were evaluated which were analyzed statistically by using one-way ANOVA. Subsequently, DOX initiated changes in the level of cardiac markers CK-MB, LDH, and troponin I, which were notably reversed by PDE. PDE was also effective against serum and urinary sodium and urinary potassium and protected against DOX-induced nephrotoxicity. Groups treated with different doses of PDE showed marked decrease in levels of cardiac and renal markers. The study concluded that the PDE extract possesses protective effects against DOX-induced cardiotoxicity and nephrotoxicity.

References

  1. Food Chem. 2014 Sep 1;158:513-20 [PMID: 24731377]
  2. Toxicol Mech Methods. 2012 Jul;22(6):424-31 [PMID: 22394338]
  3. Cancer Chemother Pharmacol. 2017 Oct;80(4):745-753 [PMID: 28785995]
  4. Clin Chim Acta. 2003 Mar;329(1-2):39-51 [PMID: 12589964]
  5. J Ethnopharmacol. 2014 Aug 8;155(1):736-43 [PMID: 24945397]
  6. PLoS One. 2016 Jul 21;11(7):e0158963 [PMID: 27441372]
  7. Pharm Biol. 2015 Jun;53(6):792-9 [PMID: 25612778]
  8. Toxicol Pathol. 2001 Nov-Dec;29(6):591-9 [PMID: 11794374]
  9. Food Sci Nutr. 2014 Nov;2(6):700-5 [PMID: 25493188]
  10. J Am Soc Nephrol. 2000 Apr;11(4):604-15 [PMID: 10752519]
  11. J Evid Based Complementary Altern Med. 2016 Oct;21(4):320-4 [PMID: 26438718]
  12. Food Chem Toxicol. 2010 Jan;48(1):436-40 [PMID: 19883716]
  13. Drug Discov Today. 2012 Feb;17(3-4):160-6 [PMID: 21983329]
  14. Front Plant Sci. 2017 May 23;8:845 [PMID: 28588600]
  15. Nat Plants. 2016 May 04;2(5):16069 [PMID: 27243661]
  16. Biomed Pharmacother. 2017 Jun;90:935-946 [PMID: 28460429]
  17. Exp Toxicol Pathol. 2011 Jul;63(5):433-41 [PMID: 20359872]
  18. Eur J Heart Fail. 2002 Jun;4(3):235-42 [PMID: 12034146]
  19. Am J Physiol. 1990 Mar;258(3 Pt 2):H793-805 [PMID: 2138424]
  20. J Cancer Res Ther. 2014 Oct-Dec;10(4):853-8 [PMID: 25579518]
  21. J Nutr Sci. 2014 Oct 08;3:e46 [PMID: 26101614]
  22. J Ethnopharmacol. 2016 Dec 24;194:457-468 [PMID: 27729284]
  23. Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):94-104 [PMID: 20728696]
  24. Cancer Res. 1988 Dec 1;48(23):6918-25 [PMID: 3141049]
  25. Free Radic Biol Med. 2006 Jul 1;41(1):46-55 [PMID: 16781452]
  26. Oxid Med Cell Longev. 2016;2016:5454963 [PMID: 28127417]
  27. J Mol Cell Cardiol. 1974 Apr;6(2):163-77 [PMID: 4828689]
  28. Nat Commun. 2015 Nov 09;6:8824 [PMID: 26549859]
  29. Microb Cell Fact. 2007 Apr 16;6:13 [PMID: 17437627]
  30. Electron Physician. 2015 Dec 20;7(8):1590-6 [PMID: 26816585]
  31. J Agric Food Chem. 2015 Apr 1;63(12):3189-95 [PMID: 25765921]
  32. Front Pharmacol. 2019 Jun 14;10:635 [PMID: 31258475]
  33. Toxicol Mech Methods. 2013 Jun;23(5):337-45 [PMID: 23256457]
  34. J Am Coll Nutr. 2005 Feb;24(1):44-50 [PMID: 15670984]
  35. Asian Pac J Trop Med. 2014 Sep;7S1:S591-8 [PMID: 25312188]

Word Cloud

Created with Highcharts 10.0.0PDEDOXnephrotoxicitycardiotoxicityextractDOX-inducedurinaryanticancerstudydosesserumsodiumpotassiumlevelscardiacmarkersDoxorubicinimportantdrugusedwidelytreatmentleukemialymphomasuitabilityenhancedhightherapeuticindexpotentialcauseremainsprimeconcerntherapeuticsdesigneddetermineeffectExperimentalratsdividedfourgroupsreceivingnormalsaline4 ml/kgalonecrude1 g/kg15 g/kgpresencerespectively21daysCardiacenzymesevaluatedanalyzedstatisticallyusingone-wayANOVASubsequentlyinitiatedchangeslevelCK-MBLDHtroponinnotablyreversedalsoeffectiveprotectedGroupstreateddifferentshowedmarkeddecreaserenalconcludedpossessesprotectiveeffectsProtectsDoxorubicin-InducedCardiotoxicityNephrotoxicity

Similar Articles

Cited By